scholarly journals Pharmacological Management of Pattern Hair Loss

2021 ◽  
Author(s):  
Sandeep Suresh Sattur ◽  
Indu Sandeep Sattur
Keyword(s):  
Hair Loss ◽  
Pharmacological Intervention ◽  
Pharmacological Treatments ◽  
Limited Evidence ◽  
Hair Transplantation ◽  
Pharmacological Management ◽  
Safety And Efficacy ◽  
Off Label ◽  
Pharmacologic Treatments ◽  
Evidenced Based

AbstractPattern hair loss (PHL) is a condition that worsens with time and the only way it can be slowed down is with pharmacological intervention. Pharmacological treatments for PHL, from an evidenced-based perspective with respect to safety and efficacy, are limited to only two drugs, minoxidil and finasteride. However, there are a host of drugs being used, off-label with limited evidence. This article attempts to review the literature on this topic, and the authors add to this, with their experience of over two decades on incorporating pharmacologic treatments along with hair transplantation in their management of PHL.

scholarly journals Pharmacological Management of Steroid-Induced Psychosis: A Review of Patient Cases

2020 ◽  
pp. 875512252097853
Author(s):  
Grace Huynh ◽  
Justin P. Reinert
Keyword(s):  
Adverse Drug Events ◽  
Data Extraction ◽  
Management Strategies ◽  
Pharmacological Intervention ◽  
Symptom Presentation ◽  
Pharmacological Management ◽  
Diagnostic And Statistical Manual ◽  
Study Selection ◽  
Cord Injury ◽  
Male Patients

Objective: To review the efficacy and safety of medications used in the management of steroid-induced psychosis. Data Sources: A comprehensive literature search was conducted using PubMed, MEDLINE, ProQuest, and Scopus between May and October 2020 using the following search terminology: “steroid-induced psychosis” OR “corticosteroid-induced psychosis.” Study Selection and Data Extraction: Definitive cases, as defined by the Diagnostic and Statistical Manual of Mental Disorders, 5th edition, were included in this review. Geriatric patients >65 years of age, those with a confounding neurological condition such as a traumatic brain or spinal cord injury, or those with active malignancy were excluded. Data Synthesis: A total of 13 patient cases were included in this review, representing 8 male patients and 5 female patients. The mean age at symptom presentation was 42.5 years. Six patients presented with delusions, 5 presented with hallucinations, and 2 presented with both manifestations; 12 patients were managed with an antipsychotic, with haloperidol being the most commonly prescribed, followed by risperidone. One patient was managed with lithium and clonazepam alone. All patients returned to their psychological baseline upon the discontinuation or decreased dose of steroids in combination with Pharmacological intervention, though the time to resolution of symptoms varied significantly. No notable adverse drug events associated with treatments were reported. Conclusions: Steroid-induced psychosis is a serious adverse effect of corticosteroid therapy; however, management strategies that combine a dose reduction or elimination of steroids, in combination with an antipsychotic medication, are effective in resolving this syndrome.

15 Triggers for the pharmacological management of delirium in palliative care: a mixed methods study

2018 ◽  
Vol 8 (3) ◽  
pp. 365.2-365
Author(s):  
Catherine L Fairfield ◽  
Anne M Finucane ◽  
Juliet A Spiller
Keyword(s):  
Palliative Care ◽  
Severe Form ◽  
Screening Tools ◽  
Pharmacological Intervention ◽  
Inpatient Setting ◽  
List Type ◽  
Structured Interviews ◽  
Retrospective Case ◽  
Pharmacological Management ◽  
High Prevalence

IntroductionDelirium is a serious neurocognitive disorder with a high prevalence in palliative care and debate regarding its management is ongoing.AimsTo describe how delirium and its symptoms is documented in patient recordsTo determine the use of delirium screening tools and how these are viewed by staffTo identify triggers for pharmacological intervention in delirium management in a terminally ill population.MethodsA retrospective case-note review concerning all patients admitted to a hospice inpatient setting between 1–17th August 2017 and semi-structured interviews with 7 hospice doctors and nurses.Results21 patients were reviewed. 62% were screened for delirium using the 4AT on admission. 76% had documented symptoms of delirium and of these 81% died without delirium resolution. There were inconsistencies in the documentation of delirium and the term itself was used infrequently. Non-pharmacological measures were poorly documented. Midazolam was the most commonly used medication. Triggers for pharmacological intervention included failure of non-pharmacological measures distress agitation and risk of patient harm. Nursing staff recognised delirium in its severe form but were less likely to do so in milder cases.ConclusionsTriggers for pharmacological intervention are in-keeping with guidelines however the level of understanding of delirium’s presentation varied between participants. This along with the high prevalence of delirium frequent use of midazolam and limited awareness and documentation of non-pharmacological measures (e.g. structured family support) highlights the need for further training and research.

Application and Approach to Hair Transplantation in Females

1997 ◽  
Vol 14 (2) ◽  
pp. 137-141
Author(s):  
Paul C. Cotterill
Keyword(s):  
Treatment Option ◽  
Hair Loss ◽  
Androgenetic Alopecia ◽  
Hair Transplantation ◽  
New Techniques ◽  
Inflammatory Dermatosis ◽  
Viable Treatment

Hair transplantation for females has become a much more viable treatment option because of recent improvements in technique employing micrografts and minigrafts as well as multiple-strip donor harvesting. The author describes how these new techniques are applied to the various types of transplantation in women, such as for androgenetic alopecia, traction alopecia, eyebrows, inactive inflammatory dermatosis, hair loss, and postrhytidectomy scarring. “Pearls,” to emphasize the contrast in the approach to the treatment of women with that of their male counterparts and the importance of assessing for realistic expectations, are described. A review of 827 females seen in consultation over the last 10 years showed that 70% of women with androgenetic alopecia were candidates for hair transplants.

scholarly journals Psychosis in Alzheimer’s Disease

2020 ◽  
Vol 20 (12) ◽  
Author(s):  
Clive Ballard ◽  
Helen C. Kales ◽  
Constantine Lyketsos ◽  
Dag Aarsland ◽  
Byron Creese ◽  
...  
Keyword(s):  
Alzheimer’S Disease ◽  
Alzheimer's Disease ◽  
Atypical Antipsychotics ◽  
Cholinesterase Inhibitors ◽  
Pharmacological Treatments ◽  
Muscarinic Agonists ◽  
Pharmacological Management ◽  
Psychological Therapies ◽  
New Treatment

Abstract Purpose of Review To review the incidence, treatment and genetics of psychosis in people with mild cognitive impairment (MCI) and Alzheimer’s disease (AD). Recent Findings Psychosis in Alzheimer’s disease (AD) has an incidence of ~ 10% per year. There is limited evidence regarding psychological interventions. Pharmacological management has focused on atypical antipsychotics, balancing modest benefits with evidence of long-term harms. The 5HT2A inverse agonist pimavanserin appears to confer benefit in PD psychosis with initial evidence of benefit in AD. Cholinesterase inhibitors give modest benefits in DLB psychosis. The utility of muscarinic agonists, lithium, glutamatergic and noradrenergic modulators needs further study. Summary Recent work has confirmed the importance of psychosis in MCI as well as AD. The lack of evidence regarding psychological therapies is an urgent knowledge gap, but there is encouraging evidence for emerging pharmacological treatments. Genetics will provide an opportunity for precision medicine and new treatment targets.

Off-Label High-Dose Secukinumab for the Treatment of Moderate-to-Severe Psoriasis

2019 ◽  
Vol 23 (4) ◽  
pp. 391-393 ◽  
Author(s):  
Michelle Phung ◽  
Arvin Ighani ◽  
Jorge R Georgakopoulos ◽  
Ron Vender ◽  
Lyne Giroux ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Dose Escalation ◽  
Case Series ◽  
Severe Psoriasis ◽  
Adult Patients ◽  
High Dose ◽  
Physician Global Assessment ◽  
Upper Respiratory Tract ◽  
Safety And Efficacy ◽  
Off Label

Background: Secukinumab is an anti-IL-17A monoclonal antibody approved for the treatment of moderate-to-severe psoriasis in adult patients. Despite its favourable safety and efficacy profile in clinical trials, some patients in clinical practice fail to respond adequately to the approved maintenance regimen of 300 mg subcutaneous monthly. Some clinicians manage these patients by using off-label high-dose secukinumab regimens, which include shortening the dosing interval to 300 mg every 2 or 3 weeks instead of monthly, or increasing the monthly dose to 450 mg. Objective: This study aims to investigate the safety and efficacy of high-dose secukinumab regimens for the treatment of psoriasis to inform real-world clinical practice. Methods: We performed a retrospective chart review at 5 dermatology clinics for adult patients diagnosed with moderate-to-severe psoriasis treated with an off-label high-dose secukinumab regimen. Efficacy was measured using the Psoriasis Area and Severity Index or a Physician Global Assessment score of 0 or 1 after dose escalation. Adverse events were recorded to assess safety outcomes. Results: Twenty-five patients were included in this case series, and 14 of them achieved efficacy from dose escalation with secukinumab based on our study endpoints. There was 1 case of the common cold and 1 upper respiratory tract infection reported after dose escalation. Conclusion: Our study provides evidence that dose escalation with secukinumab results in clinical benefit and is well tolerated among patients with moderate-to-severe psoriasis who failed to respond adequately to the approved regimen. This work necessitates larger studies to fully characterize the efficacy and long-term safety profile of secukinumab dose escalation.

scholarly journals First off Label Endovascular Clinical Experience to Treat Diffuse Cerebral Venous Sinus Thrombosis Using the INARI FlowTriever System: Case Report

2021 ◽  
Vol 12 ◽  
Author(s):  
Saif Bushnaq ◽  
Samer Abdul Kareem ◽  
Nicholas Liaw ◽  
Bader Alenzi ◽  
Muhammad Khaleeq Ahmed ◽  
...  
Keyword(s):  
Case Report ◽  
Clinical Experience ◽  
Mechanical Thrombectomy ◽  
Sinus Thrombosis ◽  
Cerebral Venous Sinus Thrombosis ◽  
Venous Sinus ◽  
Safety And Efficacy ◽  
Venous Sinus Thrombosis ◽  
Off Label ◽  
Aggressive Interventions

Anticoagulation with heparin is the current mainstay treatment for Cerebral Venous Sinus Thrombosis (CVST). Endovascular treatment is increasingly being used to treat patients with CVST who are non-responsive to anticoagulation. These more aggressive interventions include catheter-based local chemical thrombolysis, balloon angioplasty and mechanical thrombectomy with uncertain safety and efficacy. Here we describe the first reported clinical experience using the INARI FlowTriever system to treat a patient presented with focal weakness and found to have diffuse CVST.

Pharmacological management of treatment-resistant schizophrenia: advanced use of clozapine

2018 ◽  
Author(s):  
Siobhan Gee ◽  
David Taylor
Keyword(s):  
Older Adults ◽  
Adverse Events ◽  
Plasma Concentrations ◽  
Practical Experience ◽  
Treatment Resistant ◽  
Serious Adverse Events ◽  
Pharmacological Management ◽  
Off Label ◽  
Theoretical Support ◽  
The Uk

Clozapine is licensed in the UK for use in treatment-resistant schizophrenia, treatment-intolerant schizophrenia, or psychosis associated with Parkinson’s disease. As with many drugs, it is also used outside of these licensing parameters for other conditions or clinical situations—often referred to as ‘off-label’ prescribing. These off-label indications have varying degrees of theoretical support, peer-reviewed evidence, and practical experience associated with them. This chapter discusses the use of clozapine for children and adolescents, older adults, and in the treatment of aggression and mood disorders. The use of supramaximal doses of clozapine to achieve therapeutic plasma concentrations is also off-label, although adding interacting medication to reach the same result is not; these contrasting approaches are also debated. Finally, rechallenging with clozapine in patients who have previously had serious adverse events to the drug is also considered.

Hair Transplantation in Female Pattern Hair Loss

2016 ◽  
pp. 349-349
Author(s):  
Venkataram Mysore ◽  
Jayashree Venkatarm
Keyword(s):  
Hair Loss ◽  
Hair Transplantation ◽  
Female Pattern Hair Loss
Sign in / Sign up

Export Citation Format

Share Document